Laparoscopic sleeve gastrectomy with duodenojejunal bypass (LSG-DJB) has been designated as a novel bariatric surgery procedure. This combination of sleeve gastrectomy and proximal intestinal bypass theoretically offers an effective and prolonged anti-diabetes effect. This is a follow-up of our institution's previous report on the short-term effects of LSG-DJB on type 2 diabetes mellitus (T2DM), which a 68.7% remission (HbA1c <6% without diabetes medication) rate 1year after surgery. The aforementioned result was comparable to the reported remission rates of laparoscopic Roux-en-Y gastric bypass. However, the durability of remission remains unknown. The objective of this study is to investigate the medium-term (up to 5years) effects of LSG-DJB on weight loss and T2DM. In this analysis, consecutive 120 patients (female to male ratio=61:59, mean age=44.8years) with T2DM who underwent LSG-DJB from April 2007 to November 2013 and were followed up beyond 1year were included. The preoperative mean body weight and BMI were 105.7kg and 38.5kg/m2, respectively. The mean HbA1c and fasting blood glucose values were 8.9% and 194mg/dL, respectively. The mean duration of T2DM was 7.3years. Fifty-five patients (46%) were being treated with insulin prior to surgery. The follow-up rate was 97.5% at 1year, 73.3% at 3years, and 50.0% at 5years. The mean body weight was 74.9kg at 1year, 76.8kg at 3years, and 72.8kg at 5years (p<0.001, compared to the baseline). The mean percent of total body weight loss (%TWL) was 28.9, 28.6, and 30.7% at 1, 3, and 5years, respectively. Remission of T2DM was achieved at 63.6, 55.3, and 63.6% at 1, 3, and 5years, respectively. Among those who achieved diabetes remission at 1year, 10.8% of them experienced recurrence during the subsequent follow-up period. Although recurrence of T2DM is observed in some patients over time, LSG-DJB is an effective procedure for achieving significant weight loss and improvement of glycemic control, and the effects seem to be durable up to 5years.